Here we performed clinical, in vitro and in vivo analyses to assess crosstalk between the BRD/c-Myc axis and the integrin/FAK-dependent pathway in breast cancer and their potential as targets for a synthetic lethal-type therapy. This evidence concerns the gene PTK2 and breast carcinoma.